In this webinar, a detailed discussion is done on the understanding of the molecular differences between EGFR AXON 19 Deletion & EXON 21 L858R Mutatio
Speakers : Dr Pushpak Chirmade ,Dr Shailesh Bondarde ,Dr Kaushal Patel ,Dr Suhas Aagre ,Dr Sandip Ganguly
In this webinar, a detailed discussion is done on the understanding of the molecular differences between EGFR AXON 19 Deletion & EXON 21 L858R Mutatio
Speakers : Dr Pushpak Chirmade ,Dr Shailesh Bondarde ,Dr Kaushal Patel ,Dr Suhas Aagre ,Dr Sandip Ganguly
In this webinar, a detailed discussion is done on the understanding of the molecular differences between EGFR AXON 19 Deletion & EXON 21 L858R Mutatio
Speakers : Dr Pushpak Chirmade ,Dr Shailesh Bondarde ,Dr Kaushal Patel ,Dr Suhas Aagre ,Dr Sandip Ganguly
In this webinar, a detailed discussion is done on the understanding of the molecular differences between EGFR AXON 19 Deletion & EXON 21 L858R Mutatio
Speakers : Dr Pushpak Chirmade ,Dr Shailesh Bondarde ,Dr Kaushal Patel ,Dr Suhas Aagre ,Dr Sandip Ganguly
In this webinar, a detailed discussion is done on the understanding of the molecular differences between EGFR AXON 19 Deletion & EXON 21 L858R Mutatio
Speakers : Dr Pushpak Chirmade ,Dr Shailesh Bondarde ,Dr Kaushal Patel ,Dr Suhas Aagre ,Dr Sandip Ganguly
In this webinar, a detailed discussion is done on the understanding of the molecular differences between EGFR AXON 19 Deletion & EXON 21 L858R Mutatio
Speakers : Dr Pushpak Chirmade ,Dr Shailesh Bondarde ,Dr Kaushal Patel ,Dr Suhas Aagre ,Dr Sandip Ganguly
In this webinar, a detailed discussion is done on the understanding of the molecular differences between EGFR AXON 19 Deletion & EXON 21 L858R Mutatio
Speakers : Dr Sandip Ganguly ,Dr Suhas Aagre ,Dr Kaushal Patel ,Dr Shailesh Bondarde ,Dr Pushpak Chirmade
1.
Beyond What Is Visible in Myelofibrosis?
2.
FDA approves rivanetin as the first-line treatment for lung cancer.
3.
In high-risk muscle invasive urothelial cancer, adjuvant pembrolizumab improves disease-free survival.
4.
New First-Line Option for Advanced ALK-Positive Lung Cancer
5.
Certain surgical gestures during prostate removal linked to better sexual function recovery
1.
Tremelimumab: A Potential Breakthrough in Cancer Treatment
2.
The Technological Revolution in Precision Oncology and Tumor Microenvironment Therapy
3.
Artificial Intelligence for Early Cancer Detection Leveraging Multi-Omics: A Comprehensive Review
4.
Harnessing Snake Venom in Hematology: From Toxins to Life-Saving Therapeutics
5.
Unlocking the Potential of SCD: A Comprehensive Guide to Diagnosis and Treatment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VII
2.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion
3.
Updates on Standard V/S High Risk Myeloma Treatment
4.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part V
5.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation